CD163 and neoplasm: In the late temozolomide (TMZ) treatment or relapse stage, anti-PD-L1 antibody treatment significantly reduced the infiltration of CD163-positive macrophages into tumors, while a combined PD-L1 antibody and IPI-549 (a Selective PI3Kγ Inhibitor) therapy remarkably inhibited tumor growth [77].